CHEK2 and cyclic hematopoiesis: CH risk score (CHRS) that incorporates high‐risk mutations has been proposed to predict risk of developing myeloid neoplasms Mutations in TP53, PPM1D, CHEK2 confer high risk of developing t‐ myeloid neoplasms in cancer patients with cytotoxic chemotherapy/radiotherapy